As the firm continues to develop assays to run on a current batch-based MDx system, it seeks to develop a more flexible, random-access testing platform.
The firm is sketching plans to drive greater revenue growth by improving its laboratory processes and developing broader NGS panels.
The CardioGenomic Testing Alliance aims to increase the utilization of NGS panels for numerous cardiac conditions including arrhythmias and cardiomyopathies.
DiaSorin CEO Carlo Rosa said that demand for the firm's SARS-CoV-2 tests peaked during the Omicron wave in December and January but declined sharply in recent weeks.
The startup is kicking off clinical validation studies for a single-use, at-home testing platform that uses up to 32 graphene biosensors within a poker chip-sized fluidic cartridge.
The firms are launching a manual gene expression test for liver transplantation with plans to possibly develop it for Biocartis' Idylla MDx platform.
The deal with Thermo Fisher is for the development of Bio-Techne's second test in its Exosome Diagnostics portfolio, a multigene assay for kidney transplant rejection.
The group has developed a panel to detect SARS-CoV-2, other coronaviruses, and influenza A and B that also identified and differentiated six variant lineages.
The firm obtained FDA breakthrough device designation for an NGS approach to identify up to 400 bacterial pathogens used to diagnose sepsis and other bacterial infections.
The firm is offering access in Brazil to a digital assay that provides genomic insights using technology developed in a collaboration with computational pathology firm Paige.